MENU

Next Generation Sequencing-Based Tumor Genomic Profiling Aids in Detecting Hereditary Variants in Cancer Risk Genes

May 20, 2015

CHICAGO (May 20, 2015) — Cancer patients are increasingly having their tumors tested using comprehensive genomic profiling (CGP) to identify genetic mutations that can be targeted by precision therapies. A new study from investigators at Fox Chase Cancer Center in collaboration with Foundation Medicine has shown that 3-7% of patients receiving CGP could have a genetic mutation that they inherited from a parent that can also be identified using results from next generation sequencing (NGS)-based CGP.

NGS, also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies have allowed the sequencing of DNA and RNA much more quickly and cheaply than previous sequencing techniques.

“NGS is an open-market, evolving field,” said Michael J. Hall, MD, MS, director of gastrointestinal risk assessment and associate professor of medicine at Fox Chase Cancer Center. “In the clinic, it is improving speed, access, and lowering the cost of genomics.” Dr. Hall will present the study results on May 31 at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

In the study, germline, or hereditary variants, were predicted in data from 15,060 tumor samples that were analyzed by Foundation Medicine, a molecular information company based in Cambridge, MA. Analyses of variants focused on 20 hereditary cancer risk genes, determined by the American College of Medical Genetics and Genomics as “high priority for disclosure to patients if discovered by genomic testing.” The researchers assessed the pathogenicity of each variant and association with tumor histology via expert review of clinical evidence from multiple publically available variant annotation databases.

Among the tumors tested by the researchers, 30.8% had at least one germline variant in a cancer risk gene, with 521 total unique variants. A likely pathogenic variant was found in about 3.1% of tumors, and an additional 3.9% had a suspicious variant but conflicting pathogenicity data. Early-onset cancer was most strongly associated with pathogenic variants in BRCA1, a gene mostly associated with breast and ovarian cancers. Tumors for bladder cancer, squamous cell lung cancer, and kidney cancer had the most unexpected pathogenic variants, meaning these tumors were outside of the usual spectrum of cancers known to be associated with the particular gene and variant. However, data were insufficient to determine the pathogenicity for most of the variants identified.

The researchers noted some study limitations, which included the lack of data on race, family history, and controls, among others. Future short-term goals of the researchers include expanding the study to all hereditary cancer risk genes and to incorporate family history and healthy population variant rates. “More research is also needed to understand the impact that CGP has on patient behaviors,” Dr. Hall noted. “Our new genomic counseling pilot study is beginning to explore this in community-based colorectal cancer patients.”

      

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase